Luber B - Search Results

1

Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

Lordick F, Luber B, Lorenzen S, Hegewisch-Becker S, Folprecht G, Wöll E, Decker T, Endlicher E, Röthling N, Schuster T, Keller G, Fend F, Peschel C. Lordick F, et al. Among authors: luber b. Br J Cancer. 2010 Feb 2;102(3):500-5. doi: 10.1038/sj.bjc.6605521. Epub 2010 Jan 12. Br J Cancer. 2010. PMID: 20068568 Free PMC article. Clinical Trial.

2

Relationship between E-cadherin gene mutation and p53 gene mutation, p53 accumulation, Bcl-2 expression and Ki-67 staining in diffuse-type gastric carcinoma.

Fricke E, Keller G, Becker I, Rosivatz E, Schott C, Plaschke S, Rudelius M, Hermannstädter C, Busch R, Höfler H, Becker KF, Luber B. Fricke E, et al. Among authors: luber b. Int J Cancer. 2003 Mar 10;104(1):60-5. doi: 10.1002/ijc.10879. Int J Cancer. 2003. PMID: 12532420 Free article.

3

Effect of wild-type and mutant E-cadherin on cell proliferation and responsiveness to the chemotherapeutic agents cisplatin, etoposide, and 5-fluorouracil.

Fricke E, Hermannstädter C, Keller G, Fuchs M, Brunner I, Busch R, Höfler H, Becker KF, Luber B. Fricke E, et al. Among authors: luber b. Oncology. 2004;66(2):150-9. doi: 10.1159/000077442. Oncology. 2004. PMID: 15138368

4

Enhanced activation of epidermal growth factor receptor caused by tumor-derived E-cadherin mutations.

Bremm A, Walch A, Fuchs M, Mages J, Duyster J, Keller G, Hermannstädter C, Becker KF, Rauser S, Langer R, von Weyhern CH, Höfler H, Luber B. Bremm A, et al. Among authors: luber b. Cancer Res. 2008 Feb 1;68(3):707-14. doi: 10.1158/0008-5472.CAN-07-1588. Cancer Res. 2008. PMID: 18245470

5

Histone deacetylase (HDAC) 1 and 2 expression and chemotherapy in gastric cancer.

Mutze K, Langer R, Becker K, Ott K, Novotny A, Luber B, Hapfelmeier A, Göttlicher M, Höfler H, Keller G. Mutze K, et al. Among authors: luber b. Ann Surg Oncol. 2010 Dec;17(12):3336-43. doi: 10.1245/s10434-010-1182-1. Epub 2010 Jun 29. Ann Surg Oncol. 2010. PMID: 20585871

6

Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy.

Halama N, Michel S, Kloor M, Zoernig I, Benner A, Spille A, Pommerencke T, von Knebel DM, Folprecht G, Luber B, Feyen N, Martens UM, Beckhove P, Gnjatic S, Schirmacher P, Herpel E, Weitz J, Grabe N, Jaeger D. Halama N, et al. Among authors: luber b. Cancer Res. 2011 Sep 1;71(17):5670-7. doi: 10.1158/0008-5472.CAN-11-0268. Epub 2011 Aug 16. Cancer Res. 2011. PMID: 21846824

7

Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

Luber B, Deplazes J, Keller G, Walch A, Rauser S, Eichmann M, Langer R, Höfler H, Hegewisch-Becker S, Folprecht G, Wöll E, Decker T, Endlicher E, Lorenzen S, Fend F, Peschel C, Lordick F. Luber B, et al. BMC Cancer. 2011 Dec 7;11:509. doi: 10.1186/1471-2407-11-509. BMC Cancer. 2011. PMID: 22152101 Free PMC article. Clinical Trial.

8

Relevance of MET activation and genetic alterations of KRAS and E-cadherin for cetuximab sensitivity of gastric cancer cell lines.

Heindl S, Eggenstein E, Keller S, Kneissl J, Keller G, Mutze K, Rauser S, Gasteiger G, Drexler I, Hapfelmeier A, Höfler H, Luber B. Heindl S, et al. Among authors: luber b. J Cancer Res Clin Oncol. 2012 May;138(5):843-58. doi: 10.1007/s00432-011-1128-4. J Cancer Res Clin Oncol. 2012. PMID: 22290393

9

Association of amphiregulin with the cetuximab sensitivity of gastric cancer cell lines.

Kneissl J, Keller S, Lorber T, Heindl S, Keller G, Drexler I, Hapfelmeier A, Höfler H, Luber B. Kneissl J, et al. Among authors: luber b. Int J Oncol. 2012 Aug;41(2):733-44. doi: 10.3892/ijo.2012.1479. Epub 2012 May 14. Int J Oncol. 2012. PMID: 22614881

10

Epidermal growth factor receptor (EGFR) is an independent adverse prognostic factor in esophageal adenocarcinoma patients treated with cisplatin-based neoadjuvant chemotherapy.

Aichler M, Motschmann M, Jütting U, Luber B, Becker K, Ott K, Lordick F, Langer R, Feith M, Siewert JR, Walch A. Aichler M, et al. Among authors: luber b. Oncotarget. 2014 Aug 30;5(16):6620-32. doi: 10.18632/oncotarget.2268. Oncotarget. 2014. PMID: 25216514 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

170 results

Search Page